Applied Genetic Technologies exceeds enrollment target for SKYLINE trial of AGTC-501 (Ophthalmology Times)

Applied Genetic Technologies exceeds enrollment target for SKYLINE trial of AGTC-501

UF startup Applied Genetic Technologies Corp. announced it had exceeded the enrollment target in the Company’s SKYLINE trial of AGTC-501, a recombinant AAV vector-based gene therapy developed for the treatment of X-linked retinitis pigmentosa (XLRP).

According to the company, a total of 14 patients have been enrolled across the high and low dose groups, exceeding the planned target enrollment of 12.

Sue Washer, president and CEO of AGTC, a graduate company of UF Innovate | Accelerate at Sid Martin Biotech, said in a news release that the company is pleased to have reached this milestone in the clinical development of AGTC-501, which positions the company to announce interim three-month trial results in the second quarter of 2022.

Read more about Applied Genetic Technologies exceeds enrollment target for SKYLINE trial of AGTC-501.
X